ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v15.i6.20
41 pages

Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers

Joseph A. Reddy
Department of Chemistry, Purdue University, West Lafayette, IN 47907-1393
Philip S. Low
Department of Chemistry, Purdue University, West Lafayette, IN 47907-1393

要約

The vitamin folic acid (FA) enters cells either through a carrier protein, termed the reduced folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor (FR). Because folate-drug conjugates are not substrates of the former, they penetrate cells exclusively via FR-mediated endocytosis. When FA is covalently linked via its γ-carboxyl to a drug or imaging agent, FR binding affinity (KD ~ 10−10 M) is not measurably compromised, and endocytosis proceeds relatively unhindered, promoting uptake of the attached drug/imaging agent by the FR-expressing cell. Because FRs are significantly overexpressed on a large fraction of human cancer cells (e.g., ovarian, lung, breast, endometrial, renal, colon, and cancers of myeloid hematopoietic cells), this methodology may allow for the selective delivery of a wide range of imaging and therapeutic agents to tumor tissue. Folate-mediated tumor targeting has been exploited to date for delivery of the following molecules and molecular complexes: (i) protein toxins, (ii) low-molecular-weight chemotherapeutic agents, (iii) radioimaging agents, (iv) MRI contrast agents, (v) radiotherapeutic agents, (vi) liposomes with entrapped drugs, (vii) genes, (viii) antisense oligonucleotides, (ix) ribozymes, and (x) immunotherapeutic agents. In virtually all cases, in vitro studies demonstrate a significant improvement in potency and/or cancer-cell specificity over the nontargeted form of the same pharmaceutical agent. Where live animal studies have been conducted, they also reveal significant promise.


Articles with similar content:

Gene Modulation for Treating Liver Fibrosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Kun Cheng, Ram I. Mahato
Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Robert L. Sutherland, Andrew Stone, Elizabeth A . Musgrove
Putative Anti-Cancer Drug Candidate Targeting the 'PLK-1-Polo-Box Domain' by High Throughput Virtual Screening: A Computational Drug Design Study
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 3
Mohammed F. Abuzinadah, Shazi Shakil
Formulation and Physiological Factors Influencing CNS Delivery upon Intranasal Administration
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 4
Tushar Vyas, Mansoor M. Amiji, Sandip B. Tiwari
Functional Polymeric Nanoparticles: An Efficient and Promising Tool for Active Delivery of Bioactives
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 4
Senthilkumar Murugesan, Tathagata Dutta, Abhay Asthana, Manoj Tare, Surbhi Saraf, Narendra Kumar Jain, Vijayaraj Rajkumar, Manoj Nahar, Dinesh Mishra